Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
globenewswire.com
news
2022-10-18 00:00:00

WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study, the preclinical results showed that Comera's caffeine-based SQoreâ„¢ excipient did not result in local or systemic toxicity and had no impact on any measured pharmacokinetic (PK) parameters of ipilimumab when administered subcutaneously.
